Life Sciences Institute, University of Michigan, Ann Arbor, United States.
Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, United States.
Elife. 2024 Aug 28;13:RP93510. doi: 10.7554/eLife.93510.
Degradation of heparan sulfate (HS), a glycosaminoglycan (GAG) comprised of repeating units of -acetylglucosamine and glucuronic acid, begins in the cytosol and is completed in the lysosomes. Acetylation of the terminal non-reducing amino group of α-D-glucosamine of HS is essential for its complete breakdown into monosaccharides and free sulfate. Heparan-α-glucosaminide -acetyltransferase (HGSNAT), a resident of the lysosomal membrane, catalyzes this essential acetylation reaction by accepting and transferring the acetyl group from cytosolic acetyl-CoA to terminal α-D-glucosamine of HS in the lysosomal lumen. Mutation-induced dysfunction in HGSNAT causes abnormal accumulation of HS within the lysosomes and leads to an autosomal recessive neurodegenerative lysosomal storage disorder called mucopolysaccharidosis IIIC (MPS IIIC). There are no approved drugs or treatment strategies to cure or manage the symptoms of, MPS IIIC. Here, we use cryo-electron microscopy (cryo-EM) to determine a high-resolution structure of the HGSNAT-acetyl-CoA complex, the first step in the HGSNAT-catalyzed acetyltransferase reaction. In addition, we map the known MPS IIIC mutations onto the structure and elucidate the molecular basis for mutation-induced HGSNAT dysfunction.
硫酸乙酰肝素(HS)的降解始于细胞质,并在溶酶体中完成。HS 中α-D-葡萄糖胺末端非还原氨基的乙酰化对于其完全分解为单糖和游离硫酸盐是必不可少的。溶酶体膜上的常驻蛋白 - 乙酰肝素-α-葡糖胺乙酰转移酶(HGSNAT)通过接受并将细胞质乙酰辅酶 A 中的乙酰基转移到溶酶体腔中 HS 的末端α-D-葡萄糖胺上,催化这一必需的乙酰化反应。HGSNAT 的突变诱导功能障碍导致 HS 在溶酶体内异常积累,并导致常染色体隐性神经退行性溶酶体贮积症,称为黏多糖贮积症 III 型(MPS IIIC)。目前尚无批准的药物或治疗策略可治愈或控制 MPS IIIC 的症状。在这里,我们使用低温电子显微镜(cryo-EM)来确定 HGSNAT-乙酰辅酶 A 复合物的高分辨率结构,这是 HGSNAT 催化的乙酰转移酶反应的第一步。此外,我们将已知的 MPS IIIC 突变映射到结构上,并阐明突变诱导的 HGSNAT 功能障碍的分子基础。